Aktis Oncology (NASDAQ:AKTS) Given Average Rating of “Buy” by Analysts

Shares of Aktis Oncology (NASDAQ:AKTS) have been assigned an average rating of “Buy” from the five ratings firms that are covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have covered the stock in the last year is $31.25.

A number of brokerages have recently commented on AKTS. Leerink Partners initiated coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price target for the company. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Bank of America began coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price on the stock. JPMorgan Chase & Co. began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 target price for the company. Finally, HC Wainwright assumed coverage on Aktis Oncology in a report on Monday. They set a “buy” rating and a $30.00 price target on the stock.

Insider Activity at Aktis Oncology

In other news, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of the stock in a transaction on Monday, January 12th. The shares were bought at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the acquisition, the insider owned 5,671,825 shares in the company, valued at $102,092,850. The trade was a 17.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Helen Susan Kim bought 835,000 shares of the company’s stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the transaction, the director directly owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. The trade was a 17.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 6,117,776 shares of company stock valued at $110,119,968 in the last 90 days. 3.30% of the stock is owned by company insiders.

Aktis Oncology Stock Down 8.4%

Shares of NASDAQ:AKTS opened at $18.81 on Monday. Aktis Oncology has a fifty-two week low of $16.80 and a fifty-two week high of $29.16.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.